Loading clinical trials...
Loading clinical trials...
A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma
Conditions
Interventions
veltuzumab
Locations
3
France
Service Des Maladies Du Sang
Lille, Cedex, France
Centre hospitalier Lyon
Lyon, Pierre Benite Cedex, France
University of Leicester
Leicester, United Kingdom
Start Date
March 1, 2004
Primary Completion Date
November 1, 2007
Completion Date
November 1, 2007
Last Updated
August 18, 2021
NCT06667687
NCT05623982
NCT03314974
NCT04586478
NCT05054257
NCT01746849
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions